InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-27 | RTW INVESTMENTS, LP | 10% Owner | Sale | 32 | $4.13 | $132.16 | 9.56M | View ↗ | |
| 2026-03-13 | Hochman David P | Director & See Remarks | Purchase | 10.0K | $4.29 | $43K | 1.09M | View ↗ | |
| 2025-11-14 | Hochman David P | Director & See Remarks | Purchase | 5,000 | $4.07 | $20K | 612.8K | View ↗ | |
| 2025-09-19 | Aryeh Jason | Director | Purchase | 1,000 | $2.45 | $2K | 108.5K | View ↗ | |
| 2025-08-25 | Fain Eric S | Director | Purchase | 5,760 | $2.61 | $15K | 71.7K | View ↗ |
No annual data found.
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
Orchestra BioMed GAAP EPS of -$1.11, revenue of $33.48M
Orchestra BioMed Holdings, Inc. (OBIO) Surpasses Q4 Earnings and Revenue Estimates
Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Codexis (CDXS) Beats Q4 Earnings and Revenue Estimates
Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) largest shareholders are retail investors with 41% ownership, institutions own 17%
Orchestra BioMed files secondary offering of ~8M shares
Orchestra BioMed rises as trial for antihypertensive drug expands
Orchestra BioMed announces pricing of $40 million public offering